Background Antibiotic residues in poultry have the potential to have a number of harmful effects on health, including the emergence of multidrug-resistant microbial strains, allergic and an alteration of the normal flora in the intestines. The study aimed to evaluate the residue levels of enrofloxacin in chicken meat after administering berberine (BBR). Escherichia coli (E. coli) was isolated from chickens suffering from diarrhea, and its isolation was confirmed by culturing it on MacConkey agar medium. In this study, a total of one hundred chicken chicks were reared, and on the tenth day of the experiment, they were divided into five equal groups:NCG: This group represented the control and was given normal drinking water. T1: The chickens in this group were orally inoculated with E. coli at a dose of 0.5 ml containing 6x108 CFU/ml of E. coli. T2: The chickens in this group were orally inoculated with E. coli at a dose of 0.5 ml containing 6x108 CFU/ml of E. coli and were treated with enrofloxacin at a dose of 12.5 mg/kg orally through drinking water. T3 group: The chickens in this group were orally inoculated with E. coli at a dose of 0.5 ml containing 6x108 CFU/ml of E. coli and were treated with 250 mg/kg BBR through drinking water. T4 group: The chickens in this group were orally inoculated with E. coli at a dose of 0.5 ml containing 6x108 CFU/ml of E. coli and were treated with both combination enrofloxacin and BBR. Conclusion: study showed that berberine increased the residue levels of enrofloxacin in chicken meat, specifically in the thigh and liver. The docking study confirmed inhibitory activity of Cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) an enzyme responsible for the metabolism of antibiotics. Additionally, berberine demonstrated antibacterial effects against E. coli, as well as anti-inflammatory and antioxidant properties. Furthermore, histopathological examination of the intestinal broiler received BBR showed improvements and restore tissue near to normal.
Keywords | Enerofloxacin, Berberine, E. coli, Antibiotic residues, CYP450, Antioxidant, Drug docking